Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
relatlimab nivolumab melanoma | 0.33 | 0.3 | 8466 | 81 | 29 |
relatlimab | 1.15 | 0.6 | 8619 | 93 | 10 |
nivolumab | 0.98 | 0.2 | 9978 | 75 | 9 |
melanoma | 0.57 | 0.8 | 7020 | 33 | 8 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
relatlimab nivolumab melanoma | 1.48 | 0.7 | 4488 | 66 |
relatlimab nivolumab melanoma nejm | 0.07 | 1 | 4127 | 72 |
relatlimab nivolumab melanoma fda approval | 0.25 | 0.2 | 7899 | 45 |
nivolumab for metastatic melanoma | 0.08 | 0.1 | 5945 | 54 |
nivolumab and ipilimumab melanoma | 1.82 | 0.4 | 7139 | 42 |
ipilimumab and nivolumab metastatic melanoma | 0.22 | 0.1 | 6990 | 77 |
nivolumab vs pembrolizumab melanoma | 0.39 | 0.6 | 6802 | 37 |
nejm neoadjuvant pembrolizumab melanoma | 0.08 | 0.8 | 5643 | 25 |
adjuvant nivolumab in melanoma | 1.41 | 0.4 | 1115 | 16 |
pembrolizumab versus nivolumab for melanoma | 1.25 | 0.2 | 9578 | 61 |
nivolumab immunotherapy for melanoma | 1.67 | 0.9 | 6816 | 46 |
nivolumab/relatlimab | 1.12 | 1 | 7780 | 59 |
nivolumab for mesothelioma nejm | 1.33 | 0.5 | 5587 | 59 |
nivolumab for renal cell carcinoma nejm | 0.67 | 0.7 | 3108 | 32 |
pembrolizumab adjuvant melanoma nejm | 1.23 | 0.2 | 8334 | 88 |
nice ipilimumab nivolumab melanoma | 1.83 | 0.2 | 6985 | 81 |
monoclonal antibody melanoma nivolumab | 0.88 | 0.2 | 8658 | 80 |
nivolumab and relatlimab-rmbw | 1.49 | 0.8 | 9051 | 98 |